Telehealth Prescribing in Tennessee: What to Know Before December 31, 2026

The DEA's temporary telehealth prescribing rule for controlled medications expires after December 31, 2026. Here's what Tennessee patients should know about ADHD medication, telepsychiatry, and what to do now.

Share
Adult on a video visit with a psychiatric provider from home

Last Updated: November 14, 2026 · Medically reviewed by Richard Yadon, APRN, PMHNP-BC, on November 14, 2026 · Verify license

This page will be updated when the DEA publishes its final rule or extends the current flexibilities.

If you get your mental health care by video, you may have seen headlines about a December 31, 2026 telehealth prescribing deadline and wondered what it means for you. Maybe you're thinking about your next refill. Or maybe you've been considering an ADHD evaluation and aren't sure if now is the right time.

Those are fair questions. Here's a calm, clear look at what the rules say as of November 14, 2026, what's still unknown, and what you can do before the deadline.

Key facts (as of November 14, 2026):

  • Deadline: The DEA's temporary telehealth prescribing flexibilities for controlled substances expire after December 31, 2026 (DEA & HHS, 2025).
  • Status: The DEA's permanent special registration rule has been under White House review since August 25, 2026 and has not been published (OIRA, 2026).
  • What's affected: Only controlled substances, such as stimulant ADHD medications and benzodiazepines. Most antidepressants are not controlled (DEA, 2025).
  • Tennessee rule: Prescribers must check the state's Controlled Substance Monitoring Database before starting opioids, benzodiazepines, or Schedule II amphetamines (Tennessee CSMD Committee).
  • Telehealth use: About half of U.S. adults with ADHD have used telehealth for ADHD care (CDC, 2024).

What Is Changing for DEA Telehealth Prescribing on December 31, 2026?

The DEA's temporary rule that lets clinicians prescribe controlled medications by telehealth without an in-person visit expires after December 31, 2026. As of November 14, 2026, the DEA's permanent replacement, a "special registration" for telemedicine, was still under White House review and had not been published.

A 2008 federal law called the Ryan Haight Act generally requires at least one in-person medical evaluation before a clinician can prescribe a controlled substance online (21 U.S.C. § 829(e)). A controlled substance is a medication the Drug Enforcement Administration (DEA) tracks closely because it can be misused.

When COVID-19 hit in 2020, the DEA relaxed that in-person rule. It has since extended those "telemedicine flexibilities" four times. The current extension, published in the Federal Register on December 31, 2025, keeps them in place through December 31, 2026 (DEA & HHS, 2025).

The DEA proposed a special registration for telemedicine on January 17, 2025 (90 FR 6541). This would be a separate DEA registration that lets qualified clinicians prescribe some controlled medications by telehealth.

The DEA sent its final version to the White House for review on August 25, 2026. As of November 14, 2026, the White House regulatory review site still listed it as pending review (OIRA, 2026). The federal regulatory agenda lists November 2026 as the target date, but the final text has not been made public.

As of November 14, 2026, nobody outside the government knows exactly what the final rule will say or when it will take effect.

The DEA has said it keeps extending the flexibilities to avoid a sudden loss of care. When Medicare's separate telehealth flexibilities expired on September 30, 2025, fee-for-service telemedicine visits dropped 24% in the first 17 days, according to the DEA's extension notice (DEA & HHS, 2025).

Which Medications Does the DEA Rule Actually Affect?

The DEA rule only covers controlled substances, such as stimulant ADHD medications, benzodiazepines, and some sleep medications. Many common psychiatric medications, including most antidepressants and several non-stimulant ADHD options, are not controlled substances. The DEA's in-person requirement does not apply to them.

Sertraline, bupropion, and atomoxetine, for example, do not appear on the DEA's controlled substances list (DEA, 2025). The December 31 deadline doesn't change how they can be prescribed. Tennessee law and your provider's clinical judgment still apply.

Controlled medications often used in psychiatric care include (DEA, 2025):

  • Stimulant ADHD medications, like amphetamine salts and methylphenidate (Schedule II)
  • Benzodiazepines, like alprazolam or clonazepam (Schedule IV)
  • Certain sleep medications, such as zolpidem (Schedule IV)
  • Buprenorphine for opioid use disorder (Schedule III)

Telehealth has become a major way these prescriptions reach people. A study in JAMA Network Open found that the share of stimulant prescriptions written through telehealth rose from 1.4% in 2019 to 38% in 2022 (Nagappan et al., 2024). Antidepressant prescriptions by telehealth climbed from 1.5% to 31.4% over the same years.

Two narrower permanent rules already exist. One covers buprenorphine for opioid use disorder, and one covers Veterans Affairs patients. Both took effect on December 31, 2025 (DEA & HHS, 2025).

Not sure whether your medication is controlled? Ask your pharmacist or prescriber. It's a quick question, and it can save you a lot of worry.

How Could the DEA Deadline Affect ADHD Medication by Telehealth?

Stimulant ADHD medications are Schedule II controlled substances, so the DEA deadline could change how new stimulant prescriptions start by telehealth. About half of U.S. adults with ADHD have used telehealth for ADHD care (CDC, 2024). ADHD evaluations themselves are not covered by the DEA rule.

Adult ADHD is more common than many people realize. The CDC estimates that 15.5 million U.S. adults, about 1 in 16, had a current ADHD diagnosis in 2023, and more than half (55.9%) were diagnosed as adults (Staley et al., 2024).

The CDC's 2024 report also found that about half of adults with ADHD had used telehealth for ADHD care. Roughly 30.5% had used it to get an ADHD medication prescription since the pandemic began, and the report notes that medication is a first-line treatment for adults (Staley et al., 2024).

An ADHD evaluation is the structured interview, rating scales, and life history that help a clinician understand how your brain processes information. It is not a prescription. The DEA rule governs prescribing controlled medications, not evaluating or diagnosing.

Medication is also just one tool. Many adults find that coaching, skill-building, non-stimulant options, and lifestyle changes play a big part in their plan.

What about safety? Research is still developing, and the findings are mixed. A 2025 study in the American Journal of Psychiatry followed 7,944 patients age 12 and older and found that starting a stimulant by telehealth was not linked to a higher overall risk of substance use disorder (Rao et al., 2025).

The Rao study did find a higher risk of stimulant use disorder specifically. Only 19 patients in the study developed one, though, and the authors noted that other factors may explain the link.

A separate 2025 study in Health Affairs of 77,153 patients found the same overall pattern, with one exception. Adults ages 26 to 34 who started a stimulant by telehealth had a higher risk, and the researchers recommended careful screening and follow-up (Constantin et al., 2025).

If you've been putting off an ADHD evaluation because of the headlines, you don't have to wait for Washington. MindCare Health offers virtual adult ADHD evaluations across Tennessee. See our services.

How Do Tennessee Laws Affect Telepsychiatry Prescribing?

Telepsychiatry prescribing in Tennessee falls under both federal DEA rules and state law. Tennessee requires prescribers to check the state's Controlled Substance Monitoring Database (CSMD) before starting amphetamine stimulants, opioids, or benzodiazepines, and to send controlled substance prescriptions electronically. These state rules are separate from the federal deadline.

Telepsychiatry in Tennessee fills a real gap. In 2025, 95.8% of Tennessee counties were designated Mental Health Professional Shortage Areas (Tennessee Department of Health, 2025). For many people outside major cities, a video visit may be the most practical way to see a psychiatric provider.

The need is large nationally, too. In 2024, 23.4% of U.S. adults, about 61.5 million people, had a mental illness in the past year. Only about half of them (52.1%) received any mental health treatment (SAMHSA, 2025).

The CSMD is a statewide record of controlled prescriptions. State rules require prescribers to check it before prescribing an opioid, benzodiazepine, or Schedule II amphetamine at the start of a new course of treatment (Tennessee CSMD Committee).

Tennessee has also required most controlled substance prescriptions to be sent electronically since January 1, 2021 (Tenn. Code Ann. § 63-1-160; Tennessee Board of Medical Examiners). These checks help keep care safe whether a visit happens in an office or on a screen.

What Should Tennessee Patients Do Before the December 31, 2026 Deadline?

If you take a controlled medication through telehealth, you can prepare for the December 31, 2026 DEA deadline in four ways: confirm whether each medication is controlled, ask your prescriber about plans for January, request refills early, and never stop a medication without medical guidance.

Here are practical steps you can take before December 31, 2026:

  • Check your medication list. Ask whether each medication is a controlled substance.
  • Ask your provider directly. Try: "If the rules change in January, will I need an in-person visit?" A good provider will give you a straight answer, even if part of it is "we're waiting on the final rule."
  • Request refills early. Pharmacies keep holiday hours, and supply problems still happen. In 2023, 71.5% of adults taking ADHD stimulants reported trouble filling a prescription because the medication was unavailable (Staley et al., 2024).
  • Don't stop on your own. Stopping some medications suddenly can cause withdrawal or a return of symptoms. Talk with your prescriber first.
  • Get updates from official sources. Final rules appear in the Federal Register and on the DEA Diversion Control Division website.

Under the Ryan Haight Act, once a prescriber has completed an in-person evaluation, they can generally continue prescribing controlled medications by telehealth (21 U.S.C. § 829(e)). That's why some patients are asking their providers whether one in-person visit makes sense for them.

Frequently Asked Questions

Will I lose my ADHD medication on January 1, 2027?

Honest answer: it depends, because the DEA has not published its final rule. Whether ADHD medication prescribed by telehealth continues after December 31, 2026 depends on whether the DEA publishes its permanent rule, extends the current flexibilities, or sets a transition period (OIRA, 2026).

Under the Ryan Haight Act, a prescriber who has seen you in person at least once can generally keep prescribing by telehealth (21 U.S.C. § 829(e)). The best next step is a direct conversation with your prescriber.

Can I still get an ADHD evaluation by telehealth in Tennessee?

Yes. The DEA rule applies to prescribing controlled medications, not to ADHD evaluations. MindCare Health's virtual ADHD evaluation includes the same clinical interview, standardized rating scales, and input from someone who knows you well as an in-person one, and it can give you real clarity about how your brain works.

Does the deadline affect antidepressants or anxiety medications?

No for most antidepressants; yes for benzodiazepines. Most antidepressants, including SSRIs, SNRIs, and bupropion, are not controlled substances, so the DEA telehealth deadline doesn't apply to them (DEA, 2025). Benzodiazepines, sometimes prescribed for anxiety, are Schedule IV controlled substances and do fall under the rule.

Has the DEA released its final telemedicine rule?

No, not as of November 14, 2026. The DEA's special registration final rule has been under White House review since August 25, 2026, and the federal regulatory agenda lists a November 2026 target (OIRA, 2026). Check the Federal Register for the latest status.

When You're Ready, We're Here

Rule changes can feel unsettling, especially when your health is involved. But you don't have to sort it out alone, and you don't have to put your questions on hold while Washington finishes its work.

Whether you're curious about ADHD, managing stress and burnout, or looking for a psychiatric provider who takes the time to listen, a thoughtful evaluation is a smart place to start.

MindCare Health offers virtual psychiatric care and adult ADHD evaluations for adults across Tennessee, from Franklin and Nashville to Knoxville, Chattanooga, and Memphis. Appointments are private-pay, HSA/FSA eligible, and built around longer visits and direct provider access.

Schedule your evaluation when the timing feels right for you.


Written by the MindCare Health clinical team. Medically reviewed by Richard Yadon, APRN, PMHNP-BC. Verify license.

This content is for educational purposes only. It is not intended to diagnose, treat, or replace professional medical advice. If you are experiencing mental health symptoms, please consult a licensed provider. Do not stop or adjust medication without medical supervision. Federal and state prescribing rules change; this post reflects the information available on the "Last Updated" date above.


References